Search Bar & Filters
Found 1 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the pharmacokinetics similarity, safety, and immune response between Bmab1700, an intended biosimilar to nivolumab, and the United States-licensed Opdivo in participants who have had complete surgical removal of melanoma. The study focuses on adults with Stage IIB, IIC, III, or IV melanoma that has been fully resected. This phase 1 trial aims to compare these treatments as adjuvant monotherapy after surgery to understand their behavior in the body and their safety. Participants are randomly assigned to one of two groups. In the first 24 weeks Double-Blind Treatment Period, they receive intravenous infusions of either Bmab1700 or Opdivo every four weeks until disease relapse, unacceptable toxicity, or Week 20, whichever comes first. After Week 24, participants who continue in the study enter an Open-Label Treatment Period where all receive Bmab1700 every four weeks until Week 48, followed by an end-of-study visit at Week 52. Throughout the study, participants undergo regular assessments including blood sampling for drug concentration and immune response measures, monitoring for adverse events, and physical exams. Researchers measure drug levels over time, immune antibody development, and safety outcomes to evaluate the treatments. The total participation lasts up to 52 weeks, with careful monitoring to track treatment effects and participant health.